Extended-release product specialist Alkermes (NASDAQ: ALKS) reported its first-quarter earnings before the market opened for trading on Thursday, April 27. The company’s results showed that sales of its proprietary products Vivitrol and Aristada continued to grow rapidly, which once again helped its top line soar.
Let’s take a closer look at the company’s results to get a better sense of what happened during the period.
Image source: Getty Images.